Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients

M. Wenzel, C. Würnschimmel, L. Nocera, C. Collà Ruvolo, Z. Tian, SF. Shariat, F. Saad, A. Briganti, M. Graefen, LA. Kluth, P. Mandel, FKH. Chun, PI. Karakiewicz

. 2021 ; 81 (6) : 339-346. [pub] 20210305

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025811

BACKGROUND: We hypothesized that lymph node dissection (LND) at salvage radical prostatectomy may be associated with lower cancer-specific mortality (CSM) and we tested this hypothesis. METHODS: We relied on surveillance, epidemiology, and end results (2004-2016) to identify all salvage radical prostatectomy patients. Categorical, as well as univariate and multivariate Cox regression models tested the effect of LND (LND performed vs. not), as well as at its extent (log-transformed lymph node count) on CSM. RESULTS: Of 427 salvage radical prostatectomy patients, 120 (28.1%) underwent LND with a median lymph node count of 6 (interquartile range [IQR], 3-11). According to LND status, no significant or clinically meaningful differences were recorded in PSA at diagnosis, stage and biopsy Gleason score at diagnosis, except for age at prostate cancer diagnosis (LND performed 63 vs. 68 years LND not performed, p < .001). LND status (performed) was an independent predictor of lower CSM (hazard ratio [HR] 0.47; p = .03). Similarly, lymph node count (log transformed) also independently predicted lower CSM (HR: 0.60; p = .01). After the 7th removed lymph node, the effect of CSM became marginal. The effect of N-stage on CSM could not be tested due to insufficient number of observations. CONCLUSIONS: Salvage radical prostatectomy is rarely performed and LND at salvage radical prostatectomy is performed in a minority of patients. However, LND at salvage radical prostatectomy is associated with lower CSM. Moreover, LND extent also exerts a protective effect on CSM. These observations should be considered in salvage radical prostatectomy candidates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025811
003      
CZ-PrNML
005      
20211026133459.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24112 $2 doi
035    __
$a (PubMed)33666271
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wenzel, Mike $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
245    14
$a The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients / $c M. Wenzel, C. Würnschimmel, L. Nocera, C. Collà Ruvolo, Z. Tian, SF. Shariat, F. Saad, A. Briganti, M. Graefen, LA. Kluth, P. Mandel, FKH. Chun, PI. Karakiewicz
520    9_
$a BACKGROUND: We hypothesized that lymph node dissection (LND) at salvage radical prostatectomy may be associated with lower cancer-specific mortality (CSM) and we tested this hypothesis. METHODS: We relied on surveillance, epidemiology, and end results (2004-2016) to identify all salvage radical prostatectomy patients. Categorical, as well as univariate and multivariate Cox regression models tested the effect of LND (LND performed vs. not), as well as at its extent (log-transformed lymph node count) on CSM. RESULTS: Of 427 salvage radical prostatectomy patients, 120 (28.1%) underwent LND with a median lymph node count of 6 (interquartile range [IQR], 3-11). According to LND status, no significant or clinically meaningful differences were recorded in PSA at diagnosis, stage and biopsy Gleason score at diagnosis, except for age at prostate cancer diagnosis (LND performed 63 vs. 68 years LND not performed, p < .001). LND status (performed) was an independent predictor of lower CSM (hazard ratio [HR] 0.47; p = .03). Similarly, lymph node count (log transformed) also independently predicted lower CSM (HR: 0.60; p = .01). After the 7th removed lymph node, the effect of CSM became marginal. The effect of N-stage on CSM could not be tested due to insufficient number of observations. CONCLUSIONS: Salvage radical prostatectomy is rarely performed and LND at salvage radical prostatectomy is performed in a minority of patients. However, LND at salvage radical prostatectomy is associated with lower CSM. Moreover, LND extent also exerts a protective effect on CSM. These observations should be considered in salvage radical prostatectomy candidates.
650    _2
$a lidé $7 D006801
650    12
$a lymfadenektomie $x mortalita $7 D008197
650    _2
$a mužské pohlaví $7 D008297
650    12
$a prostatektomie $x metody $x mortalita $7 D011468
650    _2
$a nádory prostaty $x mortalita $x chirurgie $7 D011471
650    _2
$a program SEER $7 D018426
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Würnschimmel, Christoph $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Collà Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic $u Department of Urology, Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Kluth, Luis A $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Mandel, Philipp $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 81, č. 6 (2021), s. 339-346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33666271 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133505 $b ABA008
999    __
$a ok $b bmc $g 1714730 $s 1146318
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 81 $c 6 $d 339-346 $e 20210305 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace